Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
Lazaratos AM, Maritan SM, Quaiattini A, Darlix A, Ratosa I, Ferraro E, Griguolo G, Guarneri V, Pellerino A, Hofer S, Jacot W, Stemmler HJ, van den Broek MPH, Dobnikar N, Panet F, Lahijanian Z, Morikawa A, Seidman AD, Soffietti R, Panasci L, Petrecca K, Rose AAN, Bouganim N, Dankner M. Lazaratos AM, et al. Among authors: rose aan. Breast. 2023 Jun;69:451-468. doi: 10.1016/j.breast.2023.04.008. Epub 2023 May 1. Breast. 2023. PMID: 37156650 Free PMC article.
Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'.
Dankner M, Rose AAN. Dankner M, et al. Among authors: rose aan. Br J Cancer. 2018 May;118(9):1276-1277. doi: 10.1038/s41416-018-0012-2. Epub 2018 Mar 22. Br J Cancer. 2018. PMID: 29563631 Free PMC article. No abstract available.
Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.
Dankner M, Lajoie M, Moldoveanu D, Nguyen TT, Savage P, Rajkumar S, Huang X, Lvova M, Protopopov A, Vuzman D, Hogg D, Park M, Guiot MC, Petrecca K, Mihalcioiu C, Watson IR, Siegel PM, Rose AAN. Dankner M, et al. Among authors: rose aan. Clin Cancer Res. 2018 Dec 15;24(24):6483-6494. doi: 10.1158/1078-0432.CCR-17-3384. Epub 2018 Jun 14. Clin Cancer Res. 2018. PMID: 29903896
BRAF Mutation Class and Clinical Outcomes-Letter.
Dankner M, Rose AAN. Dankner M, et al. Among authors: rose aan. Clin Cancer Res. 2019 May 15;25(10):3188. doi: 10.1158/1078-0432.CCR-19-0080. Clin Cancer Res. 2019. PMID: 31092612 No abstract available.
Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.
Rajkumar S, Berry D, Heney KA, Strong C, Ramsay L, Lajoie M, Alkallas R, Nguyen TT, Thomson C, Ahanfeshar-Adams M, Dankner M, Petrella T, Rose AAN, Siegel PM, Watson IR. Rajkumar S, et al. Among authors: rose aan. Cell Rep. 2022 Apr 5;39(1):110634. doi: 10.1016/j.celrep.2022.110634. Cell Rep. 2022. PMID: 35385748 Free article.
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.
Dankner M, Wang Y, Fazelzad R, Johnson B, Nebhan CA, Dagogo-Jack I, Myall NJ, Richtig G, Bracht JWP, Gerlinger M, Shinozaki E, Yoshino T, Kotani D, Fangusaro JR, Gautschi O, Mazieres J, Sosman JA, Kopetz S, Subbiah V, Davies MA, Groover AL, Sullivan RJ, Flaherty KT, Johnson DB, Benedetti A, Cescon DW, Spreafico A, Zogopoulos G, Rose AAN. Dankner M, et al. Among authors: rose aan. JCO Precis Oncol. 2022 Aug;6:e2200107. doi: 10.1200/PO.22.00107. JCO Precis Oncol. 2022. PMID: 35977349 Free PMC article.
Non-small-cell lung cancer: how to manage BRAF-mutated disease.
Guaitoli G, Zullo L, Tiseo M, Dankner M, Rose AA, Facchinetti F. Guaitoli G, et al. Drugs Context. 2023 May 2;12:2022-11-3. doi: 10.7573/dic.2022-11-3. eCollection 2023. Drugs Context. 2023. PMID: 37168877 Free PMC article. Review.
42 results